Cipla`s Generic Selexipag Receives Approval in the U.S.
Zydus' Generic Selexipag Receives Approval in the U.S.
FDA Confirms Paragraph IV Patent Litigation for Uptravi (Selexipag)
Zydus receives tentative approval from US FDA for Selexipag tablets
SPIL's Generic Amphotericin B Receives Approval in the U.S.
Alembic Pharm's Generic Selexipag Receives Approval in the U.S.
ALLSCHWIL, Switzerland--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from a post-hoc pooled analysis of the Phase 3 GRIPHON and Phase 3b TRITON clinical trials evaluating the impact of early initiation of UPTRAVI® (selexipag) on disease progression, in a large population of PAH patients.
Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announced results from the Phase 3b TRITON trial, the first randomised controlled study evaluating the efficacy and safety of initial triple oral combination therapy (UPTRAVI® [selexipag], OPSUMIT® [macitentan] and tadalafil) compared to initial double oral combination therapy (placebo, macitentan and tadalafil) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension (PAH). Study results were featured as an oral presentation as part of the digital European Society of Cardiology Congress held 29 August – 1 September 2020.
FDA Confirms Paragraph IV Patent Challenge of Uptravi 207947 (Selexipag) Tablets
Actelion has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension (PAH) can now be treated with Uptravi (selexipag).